Earnings Release • Feb 3, 2021
Earnings Release
Open in ViewerOpens in native device viewer
Ieper, Belgium – February 3rd , 2021, 07.00 hrs CET
| CONFORM IFRS | FY 2020 | FY 2019 | YOY growth |
|---|---|---|---|
| in k EUR | (%) | ||
| Sales | 507,517 | 486,862 | 4% |
| Gross result | 197,988 | 196,234 | 1% |
| Gross Margin | 39.0% | 40.3% | |
| EBIT | 75,534 | 70,626 | 7% |
| EBIT in % | 14.9% | 14.5% | |
| EBITDA | 121,905 | 119,231 | 2% |
| EBITDA in % | 24.0% | 24.5% | |
| Net result | 69,299 | 60,255 | 15% |
| Net result per share (EPS) | 1.72 | 1.49 | |
| CAPEX | 24,835 | 26,632 |
Sales for the full year of 2020 were 507.5 million EUR, an increase of 4% compared to the previous year. The EUR/USD exchange rate evolution had a negative impact on sales of 1% compared to 2019.
The gross result was 198.0 million EUR or 39.0% of sales, an increase of 1% compared to 2019. R&D expenses were 15.3% of sales, G&A was at 6.1% of sales and Selling was at 2.7% of sales.
The operating result was 75.5 million EUR or 14.9% of sales, an increase of 7% compared to 70.6 million EUR in 2019.
The net result was 69.3 million EUR or 1.72 EUR per share, an increase of 15% compared to 60.3 million EUR or 1.49 EUR per share in 2019.
| CONFORM IFRS | Q4 2020 | Q4 2019 | YOY growth | Q3 2020 | SEQ growth |
|---|---|---|---|---|---|
| in k EUR | (%) | (%) | |||
| Sales | 147,400 | 127,052 | 16% | 121,568 | 21% |
| Gross result | 58,293 | 50,424 | 16% | 44,854 | 30% |
| Gross Margin | 39.5% | 39.7% | 36.9% | ||
| EBIT | 25,763 | 18,280 | 41% | 15,687 | 64% |
| EBIT in % | 17.5% | 14.4% | 12.9% | ||
| EBITDA | 37,038 | 30,773 | 20% | 26,759 | 38% |
| EBITDA in % | 25.1% | 24.2% | 22.0% | ||
| Net result | 24,012 | 15,371 | 56% | 14,905 | 61% |
| Net result per share (EPS) | 0.59 | 0.38 | 0.37 | ||
| CAPEX | 8,131 | 6,081 | 5,249 |
Sales for the fourth quarter of 2020 were 147.4 million EUR, an increase of 16% compared to the same quarter of the previous year and an increase of 21% compared to the previous quarter.
The EUR/USD exchange rate evolution had a negative impact on sales of 3% compared to the same quarter of last year and a negative impact of 1% compared to the previous quarter.
The gross result was 58.3 million EUR or 39.5% of sales, an increase of 16% compared to the same quarter of last year and an increase of 30% compared to the previous quarter.
R&D expenses were 13.7% of sales, G&A was at 5.9% of sales and Selling was at 2.5% of sales. The operating result was 25.8 million EUR or 17.5% of sales, an increase of 41% compared to the same quarter of last year and an increase of 64% compared to the previous quarter.
The net result was 24.0 million EUR or 0.59 EUR per share, an increase of 56% compared to 15.4 million EUR or 0.38 EUR per share in the fourth quarter of 2019 and an increase of 61% compared to the previous quarter.
The Board of Directors approved on January 29th, 2021 to propose to the Annual Shareholders meeting to pay out over the result of 2020 a total dividend of 2.20 EUR gross per share. This amount contains an interim dividend of 1.30 EUR per share which was paid in October 2020 and a final dividend of 0.90 EUR per share which will be payable after approval of the Annual Shareholders meeting.
The Melexis shares will start trading ex coupon on May 12, 2021 (opening of the market). The record date is May 13, 2021 (closing of the market) and the dividend will be payable as from May 14, 2021.
Melexis expects sales in the first quarter of 2021 to be in the range of 155 to 160 million euro.
For the full year 2021, Melexis expects sales growth between 15% and 20%, with a gross profit margin around 41% and an operating margin around 19% at the midpoint of the sales guidance, all taking into account a EUR/USD exchange rate of 1.21.
"After two difficult years in which we faced severe global trade tensions and an unprecedented pandemic, the end of 2020 marked a turning point for Melexis. Despite the numerous challenges that COVID-19 posed, out of adversity came opportunity: next to catering to our valued automotive customers as always, Melexis also tapped into adjacent applications that gained momentum with the COVID-19 outbreak. As a result, we concluded the year with a 4% year-over-year sales growth.
During the fourth quarter, we launched no less than 8 new products, half of which are specifically conceived for adjacent markets such as 2-/3-wheelers, home appliances and products forindustrial use. Newly launched automotive products include current sensors, a smart tire sensor and a novel motor driver for mechatronic applications, all of which serve the future car, carbon free and intelligent. Based on 2020 data, we can now
state that on average, every new car worldwide carries 13 Melexis chips on board from 11 the year before. All this makes me very proud and excited for the future.
Sales to automotive customers represented 88% of total sales, both in the fourth quarter and in the full year 2020. The portion of standard product (ASSPs) sales represented 70% of total sales in the fourth quarter and 69% in the full year 2020.
At the start of 2021, we are witnessing exceptionally strong order behavior, driven by steep restocking and revived end market demand. This condensed ordering pattern is now causing supply chain and delivery disruptions in parts of the automotive industry, the bullwhip effect in action at warp speed. Having intentionally kept its inventories at a higher than usual level in the past year, Melexis had a head start to cope with this elevated demand.
The 2021 full year sales guidance we provide is built on the one hand on meeting the strong order behavior we see today for the first half of the year, while also remaining cautious about the evolution of end market demand in the second half of the year."
The statutory auditor PwC Bedrijfsrevisoren BV has confirmed that the audit, which is substantially complete, has not to date revealed any material misstatement in the draft consolidated accounts, and that the accounting data reported in the press release is consistent, in all material respects, with the draft accounts from which it has been derived.
The company's results will be discussed in a conference call and an audiocast on Wednesday, February 3rd, 2021 at 10:30 hrs CET.
The conference call will be in English. You have to register for this conference call in advance. You can register by clicking here and filling out the requested information. After registration, you will receive the conference call number, a participant user pin, conference pin and instructions on how to join the conference call. For security purposes, all participants must register individually if they wish to join the call.
To register for the audiocast, click here.
For more information: Investor Relations Phone: +32 13 67 07 79 Email: [email protected]
Combining a passion for technology with truly inspired engineering, Melexis designs, develops and delivers innovative micro-electronic solutions that enable designers to turn ideas into applications that support the best imaginable future. The company's advanced mixed-signal semiconductor sensor and actuator components address the challenges of integrating sensing, driving and communication into next-generation products and systems that improve safety, raise efficiency, support sustainability and enhance comfort. Melexis is headquartered in Belgium and employs over 1500 people in 19 locations worldwide. The company is publicly traded on Euronext Brussels (MELE). For more information, visit www.melexis.com
Except for those statements that report the Company's historical results, the statements being made are forward looking statements. Actual results could differ materially from those projected in the forwardlooking statements. Factors which could cause actual results to differ from expectations include the following: volatility in supply and demand affecting revenues and market prices, price and availability of silicon foundry, assembly and test prices, assembly and test subcontract capacity required to meet financial targets and/or meet backlog requirements, risks and delays associated with bringing up new production capabilities or with deliveries from subcontractors, timing and market acceptance of new products, increased expenses associated with new product acceptance of new products, increased expenses associated with new product introductions of process changes, delays in developing or achieving volume production of new products, which can result in delays or failure to contribute to revenues and profits, ability of the Company to maintain its customer and vendor base and delays in and/or inability in raising additional capital.
| CONFORM IFRS | Quarter ended 31/12/2020 |
Quarter ended 31/12/2019 |
Year ended 31/12/2020 |
Year ended 31/12/2019 |
|
|---|---|---|---|---|---|
| in k EUR | audited | audited | |||
| Sales | 147,400 | 127,052 | 507,517 | 486,862 | |
| Cost of sales | -89,107 | -76,628 | -309,529 | -290,628 | |
| Gross result | 58,293 | 50,424 | 197,988 | 196,234 | |
| R&D | -20,247 | -20,497 | -77,691 | -79,558 | |
| G&A | -8,644 | -7,624 | -30,930 | -30,600 | |
| Selling | -3,638 | -4,023 | -13,834 | -15,450 | |
| Other operating result | |||||
| Operating result (EBIT) | 25,763 | 18,280 | 75,534 | 70,626 | |
| Financial result | 1,222 | -401 | 379 | -1,378 | |
| Result before taxes | 26,985 | 17,879 | 75,913 | 69,248 | |
| Income taxes | -2,973 | -2,507 | -6,613 | -8,993 | |
| Net result | 24,012 | 15,371 | 69,299 | 60,255 | |
| Net result per share in EUR | 0.59 | 0.38 | 1.72 | 1.49 |
| CONFORM IFRS | Year ended 31/12/2020 |
Year ended 31/12/2019 |
|---|---|---|
| in k EUR | audited | audited |
| Current Assets : | ||
| Cash and cash equivalents | 58,883 | 38,772 |
| Current investments | 245 | 78 |
| A/R Trade | 65,099 | 58,310 |
| A/R from related parties | 372 | 136 |
| Advance related parties | ||
| Assets for current tax | 4,695 | 1,745 |
| Assets held for sale | ||
| Other current assets | 10,637 | 9,781 |
| Inventories | 123,457 | 128,505 |
| Total current assets | 263,389 | 237,328 |
| Non-current assets : | ||
| Costs of incorporation | ||
| Property, plant and equipment | 129,949 | 143,608 |
| Leased assets | 2,731 | 4,813 |
| Financial assets | 0 | 0 |
| Intangible fixed assets | 4,650 | 5,209 |
| A/R directors | ||
| Other non-current assets | 4,203 | 3 |
| Deferred tax assets | 28,490 | 27,649 |
| Total non current assets | 170,023 | 181,282 |
| Total assets | 433,412 | 418,610 |
| CONFORM IFRS | Year ended | Year ended |
|---|---|---|
| 31/12/2020 | 31/12/2019 | |
| in k EUR | audited | audited |
| Liabilities and shareholders Equity | ||
| Current liabilities : | ||
| Bank loans and overdrafts | ||
| Derivative financial instruments | ||
| Current portion of LT debt | ||
| Lease liabilities | 1,633 | 1,825 |
| A/P trade | 18,328 | 16,139 |
| Affiliated companies | 15,759 | 15,733 |
| Accrued taxes | 473 | 3,251 |
| Accrued expenses and payroll | 11,882 | 10,643 |
| Other current liabilities | 3,433 | 4,305 |
| Deferred income | 2,799 | 2,280 |
| Total current liabilities | 54,307 | 54,176 |
| Non current liabilities : | ||
| LT debt less current portion | 62,000 | 62,000 |
| Lease liabilities | 2,122 | 3,027 |
| Deferred tax liabilities | 207 | 337 |
| Other non-current liabilities | ||
| Total non current liabilities | 64,329 | 65,364 |
| Shareholders' equity : | ||
| Shareholders' capital | 565 | 565 |
| Share premium | ||
| Treasury shares | -3,818 | -3,818 |
| Revaluation reserve Hedge | ||
| Revaluation reserve Fair value | ||
| Legal reserve | 57 | 57 |
| Retained earnings | 254,786 | 246,601 |
| Current period's profit | 69,299 | 60,255 |
| Cumulative translation adjustment | -6,113 | -4,590 |
| Equity attributable to company owners | 314,776 | 299,070 |
| Non controlling interests | 0 | 0 |
| Total shareholders equity | 314,776 | 299,070 |
| Total liabilities, shareholders' equity | 433,412 | 418,610 |
| and minority interests |
| CONFORM IFRS | Quarter ended | Quarter ended | Year ended | Year ended |
|---|---|---|---|---|
| 31/12/2020 | 31/12/2019 | 31/12/2020 | 31/12/2019 | |
| (in k EUR) | audited | audited | ||
| Cash flow from operating activities | ||||
| Net income | 24,012 | 15,371 | 69,299 | 60,255 |
| Adjustments for : | ||||
| Operating activities | 18,125 | 11,685 | 47,626 | 59,459 |
| Deferred taxes | -32 | -2,367 | -841 | -2,655 |
| Capital grants | 364 | 531 | 942 | 1,099 |
| Depreciation and amortisation | 10,773 | 11,904 | 44,453 | 46,760 |
| Depreciation leased assets | 502 | 589 | 1,918 | 1,845 |
| Accrued income tax | 8,934 | 1,369 | 4,550 | 10,374 |
| Unrealized exchange results | -2,841 | 9 | -2,213 | -604 |
| Financial result | 425 | -350 | -1,184 | 2,640 |
| Operating profit before working capital changes | 42,137 | 27,056 | 116,925 | 119,714 |
| A/R, Trade | -1,770 | 11,363 | -6,974 | 16,938 |
| A/R, affiliates | -273 | -61 | -237 | 25 |
| Other current assets | -2,907 | 1,739 | -4,756 | -2,687 |
| Other non current assets | -4,200 | -4,200 | 1 | |
| Inventories | 6,893 | -2,218 | -210 | -14,303 |
| A/P | 3,199 | 2,465 | 2,237 | -4,678 |
| A/P affiliates | 7,050 | 2,815 | 26 | 1,765 |
| Accrued expenses | -1,280 | -1,788 | 1,239 | 141 |
| Other current liabilities | -1,646 | -334 | -870 | 1,537 |
| Other non current liabilities | 275 | -49 | 389 | -721 |
| Interest paid Income tax paid |
-112 -9,561 |
-240 -3,515 |
-482 -7,327 |
-523 -22,808 |
| Cash flow from operating activities | 37,806 | 37,233 | 95,761 | 94,401 |
| 0 | 0 | |||
| Cash flow from investing activities | ||||
| Acquisition of subsidiary, net of cash acquired | ||||
| Financial fixed assets | ||||
| Purchase of PPE and intangible assets (netted) | -8,131 | -6,081 | -24,835 | -26,632 |
| Interest received | 3 | 18 | 56 | 90 |
| Investments/proceeds/ from current investments | -35 | -79 | -167 | 22 |
| Investments/proceeds/ from non current investments | ||||
| (incl. financial instruments) | ||||
| Cash provided from investing activities | -8,164 | -6,142 | -24,946 | -26,519 |
| Cash flows from financing activities Payment to acquire own shares |
||||
| Proceeds/Repayment of long-and short-term debt | 21 | 94 | 26,927 | |
| Proceeds/Repayment of bank loans and overdrafts | ||||
| Repayment leasings | 481 | -584 | -934 | -1,805 |
| Proceeds from (repayment of) related party financing | ||||
| Impact of exchange results on financing items | 2,003 | 228 | 2,272 | -661 |
| Dividend payment | -52,070 | -52,070 | -52,070 | -88,118 |
| Capital Decrease | ||||
| Non controlling interests | 0 | -10 | -10 | |
| Cash provided from financing activities | -49,565 | -52,436 | -50,639 | -63,668 |
| CTA | -26 | -31 | -65 | 37 |
| Increase/decrease in cash and cash equivalents | -19,948 | -21,377 | 20,112 | 4,250 |
| Cash at beginning of the period | 78,831 | 60,150 | 38,772 | 34,522 |
| Cash at the end of the period | 58,883 | 38,772 | 58,883 | 38,772 |
| Q4 2020 | Q4 2019 | FY 2020 | FY 2019 | |
|---|---|---|---|---|
| APAC Asia Pacific |
54% | 51% | 55% | 47% |
| EMEA Europe - Middle-East - Africa |
36% | 37% | 34% | 39% |
| NALA North America - Latin America |
10% | 12% | 11% | 14% |
| TOTAL | 100% | 100% | 100% | 100% |
Building tools?
Free accounts include 100 API calls/year for testing.
Have a question? We'll get back to you promptly.